DBDebasish Basu

Debasish Basu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Debasish Basu has a total of 193 co-authors. Here are the top co-authors by number of shared publications:

  • Abhishek Ghosh

    Postgraduate Institute of Medical Education and Research, Chandigarh, India

    14 shared publications
  • Abhishek Ghosh

    Drug De-addiction and Treatment Centre, Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India

    7 shared publications
  • Surendra Kumar Mattoo

    Drug De-addiction & Treatment Centre (DDTC), Department of Psychiatry, Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, India

    7 shared publications
  • Bhagyalakshmi Nanjayya Subodh

    Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, India

    6 shared publications
  • Tathagata Mahintamani

    Department of Addiction Medicine, Lokopriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur, Assam, India

    6 shared publications
  • Nitin Gupta

    Gupta Mind Healing and Counselling Centre, Chandigarh, India

    5 shared publications

Latest Publications

  • Telemedicine‐assisted buprenorphine induction versus standard of care: A randomized controlled non‐inferiority trial

    by Harpreet S. Dhillon, Abhishek Ghosh, Shalini Naik, Subodh Nanjayya, Abhishek Verma, Debasish Basu

    Background and aims: Although buprenorphine‐based opioid agonist maintenance treatment (OAMT) is effective, logistical, economic and stigma‐related barriers limit access. Telemedicine‐Assisted Buprenorphine Induction (TABI) may address these barriers. This study evaluated the non‐inferiority of TABI compared with the Standard of Care (SoC) for buprenorphine induction. Design: Open‐label, two‐arm, randomized controlled non‐inferiority trial. The induction period lasted 7 days, after which all participants continued buprenorphine‐based OAMT as routine care. Follow‐up assessments were done at one week and one month. Settings: Addiction treatment center, Chandigarh, India. Participants: Adults with opioid use disorder (OUD) meeting ICD‐11 ( International Classification of Diseases , 11th Revision) criteria, recruited between December 2023 and August 2024. A total of 138 participants were randomized (SoC = 70; TABI = 68). The mean age of participants was 28.2 years. Most participants were male (98.55%). Intervention: SoC involved supervised in‐person buprenorphine induction for three days. TABI consisted of in‐person induction on Day 1, followed by telemedicine‐based follow‐ups for Days 2–6. In‐person review on Day 7 in both arms. Measurements: Primary outcome: treatment retention at one week, using a 15% non‐inferiority margin. Secondary outcomes: abstinence from illicit opioids, withdrawal symptoms, cravings, quality of life, satisfaction, therapeutic alliance and medication adherence. Findings: The one‐week retention rate was 75.71% in the SoC group and 82.35% in the TABI group, with an absolute difference of 6.64% [95% confidence interval (CI) = −6.88% to 20.16%]. The lower limit of the 95% confidence interval for the difference (−6.88%) is above the pre‐specified non‐inferiority margin, confirming the non‐inferiority of TABI compared with SoC. Both groups showed statistically significant improvements in withdrawal symptoms, cravings and quality of life over time, with no statistically significant group differences. Patient satisfaction, therapeutic relationships, adherence and side effects were comparable between groups. Conclusion: This randomized controlled trial found that telemedicine‐assisted buprenorphine induction was non‐inferior to standard care for one‐week retention in treatment among adults with opioid use disorder. As such, it offers a patient‐centred alternative to standard care and has the potential to reduce treatment barriers and improve access in resource‐limited settings.


  • Open Access

    Cannabis and psychopathology: 2024 Snapshot of a meandering journey

    by Tathagata Mahintamani, Diptadhi Mukherjee, Debasish Basu

    Background: Cannabis has been associated with psychopathology since ancient times, but controversies continue despite important advances in the field. This article is the fourth one in our decadal series of review articles that have been providing an update snapshot of the meandering journey of the research findings in this area. Aims: This narrative review of a comprehensive literature search over the past 10 years aims to provide an update and current understanding, while raising unanswered questions for the future, focusing on the following areas: (a) nosological changes in cannabis-related psychiatric syndromes; (b) psychopathology associated with the newer category of synthetic cannabinoids; (c) cannabis withdrawal syndrome); (d) cannabis and psychosis; (e) cannabis and mood disorders; (f) cannabis and suicidality; (g) prenatal cannabis use and psychopathology in the offspring; (h) effect of recent liberal policy overhaul on cannabis control in certain countries/areas on psychopathology and adverse outcomes; (i) cannabis and cognition; and (j) cannabis, psychopathology, and genetics. Methods: The data search strategies involved a combination of electronic databases and manual hand-searching of relevant publications and cross-references using selected search terms. The primary electronic search focused on Medline and PubMed Central databases but extended to databases such as Google Scholar, PsychINFO, Scopus, and Ovid for specific sections. Key references identified through electronic and manual searches provided additional material. Inclusion criteria for the review spanned studies published between January 2014 and June 2024, with more emphasis placed on recent studies (post-2020) while ensuring historical coverage. Results: The narrative review aimed to be comprehensive, including a broad range of research without strict methodological exclusions. Strengths and limitations of cited research are discussed when applicable, maintaining consistency with three prior reviews. We focused on psychopathology and psychiatric syndromes, human (rather than animal) studies, and applied (rather than basic) research. We have only focused on policy with reference to psychopathology and not on that entire area because that would be beyond the scope of this article. There are important updates in all the areas covered. There are newer syndromal entities in ICD-11, which also includes synthetic cannabinoids for the first time. Cannabis withdrawal syndrome has been better characterized. The association between cannabis and psychosis has been robustly established especially for very high-potency cannabis and for vulnerable populations, particularly young people. Work is in progress elucidating the causal mechanisms. The links between cannabis and mood disorders as well as suicidality and cognitive impairment are better characterized, though questions remain. Recent liberalizing policies on cannabis have produced newer findings on prenatal and accidental cannabis use (with deleterious effects on the offspring) and on later psychopathology (mixed findings, but a documented increase in emergency visits related to recent cannabis use). This is an area which will require active monitoring for new data. Conclusion: The field of cannabis use and psychopathology continues to collect new data and settle some old controversies while raising new questions, which are important to address in view of the wide use of cannabis worldwide and its implications for public health.


  • Open Access

    Mortality trends and causes of death in a South African hospital complex pre- and during COVID-19

    by Khanyisile M. Tshabalala, Inger Fabris-Rotelli, Debashis Basu, Magriet Myburgh, Fareed Abdullah

    Background: Before coronavirus disease 2019 (COVID-19), global health was improving, with declining mortality trends. The pandemic disrupted this progress, increasing mortality in South Africa between April 2020 and March 2022. Pre-pandemic data establishes a baseline for assessing COVID-19’s impact on all-cause mortality. Objectives: This study examines changes in hospital-based mortality trends in a Gauteng hospital complex from April 2018 to March 2022, addressing the scarcity of such studies during the COVID-19 era. Method: A retrospective review of 7815 deaths from April 2018 to March 2022 was conducted. Chi-squared tests were used to analyse deaths by age group and gender, with correlations reported. Results: Mortality rates rose from 3.2% in 2018–2019, peaked at 5.1% in 2020–2021, and declined to 4.2% in 2021–2022. Patients aged 15 years–64 years had the highest death rates, with an increase among those over 65. Male deaths exceeded female deaths, with the smallest difference observed in 2020–2021. Leading causes of death included diseases of the circulatory and respiratory systems, neoplasms, digestive system diseases, and infectious and parasitic diseases. Conclusion: The study highlights COVID-19’s impact on mortality, showing variations by year, age, gender, and disease. Contribution: Excess non-COVID-19 deaths likely stemmed from disrupted healthcare services. These findings underscore the need for ongoing monitoring of hospital mortality to identify pandemic-related service disruptions and guide interventions to strengthen healthcare services, improve access to care, and enhance referral systems during unexpected disasters.


  • Professional Ethics and Boundaries

    by Fernando Lolas, Debasish Basu


  • Open Access

    Norman Sartorius: The Mental Health Crusader Who Simply Won’t Stop

    by Debasish Basu

    Professor N. Sartorius, MD, PhD, FRCPsych, previously the Director of the Mental Health Program of the World Health Organization and President of the World Psychiatric Association and of the European Psychiatric Association, now serves as President of the Association for the Improvement of Mental Health Programs, a nongovernmental organization located in Geneva, Switzerland. Professor Sartorius holds several professorial positions in Europe, the USA, and elsewhere. He has published more than 500 papers in peer-reviewed journals and authored, co-authored, edited, or co-edited more than 120 books. However, more than all these, Professor Sartorius will be remembered by posterity as a relentless crusader for mental health and against stigma toward mental illness. Professor Sartorius has focused his sustained attention on the reduction of the stigma of mental illness, on the comorbidity of mental and physical disorders, and on support to carers of people with mental disorders. He has been particularly interested in the education of young professionals and conducted leadership and professional skills courses in some 60 countries involving more than 3000 psychiatrists early in their careers. In this interview, he briefly but importantly talks about the phases of his life, work, passion, vision, and mission, and leaves important messages for future generations.